Article By:
ChinaBio® Today
Saturday, August 6, 2016 4:16 PM EDT
Hutchison China MediTech will contribute $50 million to accelerate global clinical development of savolitinib, a c-MET inhibitor that Chi-Med partners with AstraZeneca.
In this article: AZN, SRNE, LGND, OSN, HCM
